GlassScriptPhysician profile
Sushil Jain
NPI 1497749238
$1,741.28
in general payments reported to CMS, 2019-2025
22 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $11.29 · 2021: $163 · 2022: $74.27 · 2023: $105 · 2024: $391 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $580.37 | 2020-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $201.47 | 2019 | |
| Lilly USA, LLC | $179.42 | 2019-2025 | Omvoh |
| Eisai INC. | $156.13 | 2019 | |
| Genentech USA, INC. | $149.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.50 | 2021-2025 | Xifaxan |
| Abbvie INC. | $67.96 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $27.09 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $23.78 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.47 | 2022 | |
| Intercept Pharmaceuticals, INC. | $21.23 | 2024 | |
| Exact Sciences Corporation | $17.40 | 2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $16.90 | 2024 | |
| Exelixis INC. | $16.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $16.22 | 2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $14.28 | 2021 | |
| Kyowa Kirin, INC. | $14.16 | 2019 | |
| Shire North American Group INC | $12.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushil Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.